A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-08-14
DOI
10.3389/fimmu.2019.01943
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy
- (2019) Beatriz Sanchez-Correa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma
- (2018) Cédric Rossi et al. OncoImmunology
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
- (2016) Bruce D. Cheson et al. ANNALS OF HEMATOLOGY
- Breakthrough therapies in B-cell non-Hodgkin lymphoma
- (2016) C. Y. Cheah et al. ANNALS OF ONCOLOGY
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- 2016 US lymphoid malignancy statistics by World Health Organization subtypes
- (2016) Lauren R. Teras et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma
- (2016) L He et al. Blood Cancer Journal
- Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas
- (2016) Marie Tosolini et al. OncoImmunology
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Obinutuzumab in hematologic malignancies: Lessons learned to date
- (2015) Tim Illidge et al. CANCER TREATMENT REVIEWS
- Improving natural killer cell cancer immunotherapy
- (2015) Melissa M. Berrien-Elliott et al. Current Opinion in Organ Transplantation
- Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
- (2015) Simone Battella et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- EZH2 Mutations in Follicular Lymphoma from Different Ethnic Groups and Associated Gene Expression Alterations
- (2014) S. Guo et al. CLINICAL CANCER RESEARCH
- Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes
- (2014) Emilie Decaup et al. IMMUNOLOGY LETTERS
- Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies
- (2014) Minh Ngoc Duong et al. mAbs
- Cell Growth in Aggregates Determines Gene Expression, Proliferation, Survival, Chemoresistance, and Sensitivity to Immune Effectors in Follicular Lymphoma
- (2013) Pauline Gravelle et al. AMERICAN JOURNAL OF PATHOLOGY
- Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
- (2013) M. Brodtkorb et al. BLOOD
- Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma
- (2013) M. R. Green et al. BLOOD
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
- (2013) J. Radford et al. BLOOD
- Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma
- (2013) Danielle Shafer et al. LEUKEMIA RESEARCH
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity
- (2013) Patricia Amé-Thomas et al. SEMINARS IN CANCER BIOLOGY
- An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma
- (2012) A. James Watkins et al. PLoS One
- Innate predisposition to immune escape in follicular lymphoma cells
- (2012) Pauline Gravelle et al. OncoImmunology
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
- (2011) E. Campo et al. BLOOD
- Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
- (2011) S. Dalle et al. MOLECULAR CANCER THERAPEUTICS
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
- (2010) M. S. Braza et al. HAEMATOLOGICA
- Rituximab inhibits B-cell receptor signaling
- (2009) S. Kheirallah et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More